Filing identity and reporting period
Important mismatch: The request identifies Neurogene Inc., but the supplied filing is Aquinox Pharmaceuticals, Inc. (Nasdaq: AQXP), Form 10-Q for the quarter ended June 30, 2019, filed August 1, 2019. This summary reflects the supplied filing, not Neurogene.
The unaudited statements cover the three and six months ended June 30, 2019, with comparisons to 2018. Amounts below are U.S. dollars.
Financial results and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $25.0 million | $0 | $25.0 million |
| Operating expenses | $0.428 million | $22.310 million | $3.087 million | $37.127 million |
| Operating income (loss) | ($0.428 million) | $2.690 million | ($3.087 million) | ($12.127 million) |
| Other income, net | $0.427 million | $0.228 million | $0.878 million | $0.422 million |
| Net income (loss) | ($0.001 million) | $2.918 million | ($2.209 million) | ($11.705 million) |
- Q2 2019 R&D expense was a $1.995 million credit, reflecting revised vendor accrual estimates; G&A was $2.423 million. The filing reports no product revenue, so revenue-based margins are not meaningful.
- At June 30, 2019, cash and cash equivalents were $72.7 million, down from $76.9 million at December 31, 2018. Working capital was $72.0 million; total assets were $73.7 million and stockholders’ equity was $72.3 million.
- Six-month operating cash use was $4.226 million, versus $6.408 million in 2018. Investing cash flow was zero in 2019; financing cash use was $0.004 million. Cash declined by $4.228 million over the six months.
- No material conventional debt balance is reported. Lease liabilities totaled $0.454 million ($0.201 million current and $0.253 million non-current); finance lease obligations were $0.002 million.
- Accumulated deficit was $232.3 million. The filing does not present a gross margin measure.
Material changes versus the prior comparable period
- Revenue fell to zero from $25.0 million in both 2018 comparison periods. The prior-year revenue was the non-refundable upfront payment under the Astellas rosiptor collaboration; the agreement was terminated in November 2018.
- Operating costs fell substantially after rosiptor development was halted following failure of its Phase 3 Leadership 301 trial and after 2018 workforce and facility restructurings. Q2 2019 R&D included a credit rather than a charge.
- Six-month net loss narrowed to $2.2 million from $11.7 million, primarily reflecting lower operating expenses; this comparison also includes the prior-year $25.0 million collaboration revenue.
- Cash used in operations improved year over year, while cash and cash equivalents declined from year-end 2018.
Outlook, commentary, and risks
- Aquinox stated that it had no product candidates in clinical development or identified for clinical development and no internal R&D capabilities after reducing its workforce from 56 to eight employees.
- Management was evaluating strategic alternatives, including a merger, in-licensing or acquisition of products, and advancement of research-stage compounds. If suitable opportunities could not be identified, the board might consider returning capital to stockholders and dissolving the business.
- Management believed existing capital would fund operations for at least 12 months from the filing, but anticipated needing substantial future financing. This is a forward-looking estimate and actual cash use could differ.
- Key risks include failure to secure viable products or a transaction, inability to raise capital on acceptable terms, potential dilution in a merger or financing, and costs or execution risks from restructuring and rebuilding capabilities. The filing also cites foreign-currency exposure; the company did not hedge that exposure.
- Q2 included a $2.0 million downward revision to estimated costs for the July 2018 restructuring based on vendor information. A further $0.7 million or more of costs had been expected in 2019 under the separate November 2018 restructuring; $0.168 million remained expected at June 30, 2019.
- The company reported effective disclosure controls and no material change in internal control over financial reporting during the period. It reported no off-balance-sheet arrangements and no specific legal proceeding in the supplied text.
Most important facts for investors to verify
- Confirm issuer identity: the supplied filing is for Aquinox Pharmaceuticals, not Neurogene Inc.
- Verify the status and outcome of the strategic-options review, including any merger, licensing, acquisition, capital return, or dissolution plans.
- Assess whether the stated 12-month cash runway remains supportable given current operating costs, restructuring obligations, and transaction plans.
- Confirm whether any product candidates have since been identified or advanced, and what capabilities and funding would be required.
- Check subsequent filings for changes to cash, share count, financing needs, and restructuring estimates.